




**EASL**

LIVER  
CANCER  
SUMMIT

Estoril, Portugal  
20–22 April

2023



# Abstract book

#LiverCancerSummit

[easl.eu/lcs2023](http://easl.eu/lcs2023)

P08-20

## TKI treatments for HCC before liver transplantation: a collaborative European study

Chiara Mazzairelli<sup>1</sup>, Sherrie Bhoori<sup>2</sup>, Samuele Grandi<sup>2</sup>, Salvatore Gruttadauria<sup>3</sup>, Jose Ignacio Herrero<sup>4</sup>, Aliaksei Shcherba<sup>5</sup>, Caroline den Hoed<sup>6</sup>, Damiano Patrono<sup>7</sup>, Renato Romagnoli<sup>7</sup>, Massimo De Giorgio<sup>8</sup>, Alessandro Ioglio<sup>8</sup>, Stefano FAGIUOLI<sup>8</sup>, Olivier Detry<sup>9</sup>, Pierluigi Toniutto<sup>10</sup>, Maria Francesca Donato<sup>11</sup>, Grazia Conte<sup>12</sup>, Raffaella Viganò<sup>1</sup>, Tommaso Maria Manzia<sup>13</sup>, Alfonso Avolio<sup>14</sup>, Vincenzo Mazzaferro<sup>2</sup>, Luca Saverio Belli<sup>1</sup>

<sup>1</sup>ASST Niguarda, Hepatology and Gastroenterology, Milan, Italy, <sup>2</sup>Istituto Nazionale dei Tumori, Milano, Italy, <sup>3</sup>ISMETT, Palermo, Italy, <sup>4</sup>University of Navarra, Pamplona, Spain, <sup>5</sup>RSP Center for Organ and Tissue Transplantation, Minsk · Division of Liver transplantation and HPB surgery, Minsk, Belarus, <sup>6</sup>Erasmus University Medical Center, department of Gastroenterology and Hepatology, Rotterdam, Netherlands, <sup>7</sup>Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, General surgery 2U, Torino, Italy, <sup>8</sup>ASST Papa Giovanni XXIII Hospital, Hepatology, Bergamo, Italy, <sup>9</sup>Chu De Liège, Dpt of Abdominal Surgery and Transplantation, Luik, Belgium, <sup>10</sup>Hospital Santa Maria della Misericordia, Udine, Italy, <sup>11</sup>Policlinico of Milan, Gastroenterology and Hepatology, Milano, Italy, <sup>12</sup>Marche Polytechnic University, epato-Pancreato-Biliary and Transplant Surgery, Department of Experimental and Clinical Medicine,, Ancona, Italy, <sup>13</sup>Hospital Tor Vergata Roma, Department of Surgery Science, Roma, Italy, <sup>14</sup>Catholic University of the Sacred Heart, department of surgery , Milano, Italy

Email: [chiamazzairelli@hotmail.com](mailto:chiamazzairelli@hotmail.com)

**Background and Aims:** Recent advances in systemic treatments for hepatocellular carcinoma (HCC) have prompted the discussion regarding their possible role for downstaging advanced HCC prior to liver transplantation (LT) or for bridging to LT to prevent tumor progression and reduce the dropout risk.

**Method:** Data of patients with HCC treated with different TKI before LT were collected using an online Survey in 16 different centres across Europe.

**Results:** 48 patients with a mean age of 60 years and receiving a LT between December 2006 and September 2022 were enrolled. 26 patients were treated with TKI with a downstaging purpose, while 22 received TKI as a bridging treatment to LT. 34 patients (71%) received sorafenib, 13 lenvatinib (27%) and 1 patient (2%) a sequential therapy with sorafenib-regorafenib. 41 patients (85%) received at least one locoregional treatment before LT. 27 patients were Milan-in at listing (56%). After a median follow up of 464 days (20-3005), 6 patients (12.5%) experienced recurrence of HCC after LT (3 patients were Milan-in and 3 Milan out at listing). We observed 4 cases of early mild-moderate graft rejection (8%) and 8 (16%) cases of vascular complications (artery thrombosis or arterial bleeding) early after LT. All vascular complications occurred in the group of patients treated with TKI as downstaging treatment, with last administration of TKI 158 days before LT.

**Conclusion:** This is largest series of patients receiving TKI pre-LT reported to date which confirms very favorable short-term outcome (93% one-year overall survival).

**Figure:**

<b>Table 1. Patients Main features (=48 pts)</b>	
<b>Mean Age, (IQR)</b>	60 (44-69)
<b>Underlying liver disease, n (%)</b>	
- Viral Hepatitis	- 31 (64.5)
- Alcohol	- 9 (18.7)
- MAFLD	- 6 (12.5)
- Other	- 3 (6.25)
<b>Clinically Significant portal Hypertension with Esophageal Varices, n (%)</b>	10 (21)
<b>Type of donor, n (%)</b>	
- DBD	- 37 (77)
- DCD	- 10 (21)
- Living donor	- 1 (2)
<b>Alfa-fetoprotein at listing, m (IQR)</b>	193 (1-2986)
<b>Milan criteria at listing, n (%)</b>	
- Milan in	- 27 (56)
- Milan out	- 21 (43)
<b>Patients received at least one locoregional treatments before LT, n (%)</b>	41 (85%)
- <b>Resection</b>	- 11 (23)
- <b>TACE, TARE, TAE</b>	- 30 (62.5)
- <b>Ablation</b>	- 14 (29)
- <b>SRBT</b>	- 2 (4)
<b>Purpose of TKIs treatment</b>	
- <b>Bridging</b>	- 22 (45)
- <b>Downstaging</b>	- 26 (55)
<b>Type of TKIs, n (%)</b>	
- <b>Sorafenib</b>	- 34 (71)
- <b>Levatinib</b>	- 13 (27)
- <b>Regorafenib</b>	- 1 (2)
<b>Time from last dose of TKI to LT, m (IQR)</b>	
- <b>Bridging group</b>	- 21 (0-113)